Dosing of antibiotics in obesity

Current Opinion in Infectious Diseases

Volumn 25, Issue 6, 2012, Pages 634-649

  Janson, Brett ^a   Thursky, Karin ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

antibiotics; dosing; obesity; pharmacokinetic pharmacodynamic

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFAZOLIN; CEFEPIME; CEFOXITIN; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERTAPENEM; GENTAMICIN; LEVOFLOXACIN; LINCOSAMIDE; LINEZOLID; MACROLIDE; MEROPENEM; MOXIFLOXACIN; NITROIMIDAZOLE; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TETRACYCLINE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BODY MASS; CONTINUOUS INFUSION; DECISION MAKING; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GLOMERULUS FILTRATION RATE; HUMAN; HYDROPHILICITY; INFECTION; INFECTION RISK; KIDNEY FUNCTION; KIDNEY METABOLISM; LIPOPHILICITY; LIVER METABOLISM; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORBID OBESITY; NEPHROTOXICITY; OBESITY; PHARMACODYNAMICS; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; SKIN INFECTION; STOMACH DISTENSION; STOMACH EMPTYING; SURGICAL INFECTION; SURGICAL PATIENT; TREATMENT INDICATION; URINARY EXCRETION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HUMANS; OBESITY;

EID: 84870063213     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328359a4c1     Document Type: Review

References (161)

1. Squires DA. Tracking trends in health system performance: issues in international health policy: explaining high healthcare spending in the United States: an international comparison of supply, utilization, prices, and quality. Issue Brief (Commonw Fund) 2012; 10:1-14.
2. Silber JH, Rosenbaum PR, Kelz RR, et al. Medical and financial risks associated with surgery in the elderly obese. Ann Surg 2012; 256:79-86.
3. Huttunen R, Laine J, Lumio J, et al. Obesity and smoking are factors associated with poor prognosis in patients with bacteraemia. BMC Infect Dis 2007; 7:13.
4. Huttunen R, Syrjanen J. Obesity and the risk and outcome of infection. Int J Obes (Lond) 2012. doi:10.1038/ijo.2012.62 [Epub ahead of print]
5. Harrop JS, Styliaras JC, Ooi YC, et al. Contributing factors to surgical site infections. J Am Acad Orthop Surg 2012; 20:94-101.
6. Wakefield H, Vaughan-Sarrazin M, Cullen JJ. Influence of obesity on complications and costs after intestinal surgery. Am J Surg 2012. [Epub ahead of print]
7. Schuster JM, Rechtine G, Norvell DC, Dettori Jr. The influence of perioperative risk factors and therapeutic interventions on infection rates after spine surgery: a systematic review. Spine 2010; 35 (9 SUPPL.):S125-S137.
8. Marti A, Marcos A, Martinez JA. Obesity and immune function relationships. Obes Rev 2001; 2:131-140. (Pubitemid 33755922)
9. Milner JJ, Beck MA. The impact of obesity on the immune response to infection. Proc Nutr Soc 2012; 71:298-306.
10. Louie JK, Acosta M, Samuel MC, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis 2011; 52:301-312.
11. Van Kerkhove MD, Vandemaele KA, Shinde V, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011; 8:e1001053.
12. Weber DJ, Rutala WA, Samsa GP, et al. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. J Am Med Assoc 1985; 254:3187-3189. (Pubitemid 16206968)
13. Weber DJ, Rutala WA, Samsa GP, et al. Impaired immunogenicity of hepatitis B vaccine in obese persons. N Engl J Med 1986; 314:1393. (Pubitemid 16122481)
14. Eliakim A, Schwindt C, Zaldivar F, et al. Reduced tetanus antibody titers in overweight children. Autoimmunity 2006; 39:137-141. (Pubitemid 43675257)
15. Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 2004; 30:18-32. (Pubitemid 38147104)
16. Roe JL, Fuentes JM, Mullins ME. Underdosing of common antibiotics for obese patients in the ED. Am J Emerg Med 2012; 30:1212-1214.
17. Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010; 375:248-251.
18. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007; 27:1081-1091.
19. Cheymol G. Drug pharmacokinetics in the obese. Fundam Clin Pharmacol 1988; 2:239-256.
20. Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet 1993; 25:103-114. (Pubitemid 23232390)
21. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clinic Pharmacokinet 2000; 39:215-231.
22. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis 1997; 25:112-118. (Pubitemid 27293084)
23. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49:71-87.
24. Jain R, Chung SM, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 2011; 90:77-89. See [26].
25. Leykin Y, Miotto L, Pellis T. Pharmacokinetic considerations in the obese. Best Pract Res Clin Anaesthesiol 2011; 25:27-36. See [26].
26. Morrish GA, Pai MP, Green B. The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol 2011; 7:697-706. This and [24] and [25] are recent reviews on pharmacokinetic considerations in obese patients.
27. Brill MJ, Diepstraten J, van Rongen A, et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 2012; 51:277-304. Comprehensive comparison of drug metabolism changes seen in obese patients.
28. Abernethy DR, Greenblatt DJ. Drug disposition in obese humans. An update. Clin Pharmacokinet 1986; 11:199-213. (Pubitemid 16079739)
29. Van Bambeke F, Tulkens PM. Macrolides: pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2001; 18 (SUPPL. 1):S17-S23. (Pubitemid 33713498)
30. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58:119-133. (Pubitemid 39043992)
31. World Health Organisation. Obesity and overweight Fact sheet N8311. http://www.who.int/mediacentre/factsheets/fs311/en/index.html. [Accessed on 10 July 2012]
32. Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm 1974; 8:650-655.
33. Han PY, Duffull SB, Kirkpatrick CM, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007; 82:505-508. (Pubitemid 47622534)
34. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44:1051-1065. (Pubitemid 41356391)
35. Garrow JW. J. Quetelet's Index (W/H2) as a measure of fatness. Int J Obes 1985; 9:147-153.
36. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983; 24:643-647. (Pubitemid 13092243)
37. Duffull SB, Dooley MJ, Green B, et al. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet 2004; 43:1167-1178. (Pubitemid 40013182)
38. Du Bois D, Du Bois E. Clinical calorimetry: tenth paper. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17:863.
39. Mosteller R. Simplified calculation of body surface area. N Engl J Med 1987; 317:1098.
40. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363:157-163.
41. Spellwin G. BMI for Men Increases Health Insurance for Bodybuilders and Athletes Available from http://bodybuilding.elitefitness.com/bmi-men- bodybuilder-athletes?s=7938c37dbc8b3fe898914db0aeee5605. [Accessed on 12 June 2012]
42. Pai MP, Paloucek FP. The origin of the 'ideal' body weight equations. Ann Pharmacother 2000; 34:1066-1069. (Pubitemid 30660784)
43. Maddox A, Horowitz M, Wishart J, Collins P. Gastric and oesophageal emptying in obesity. Scand J Gastroenterol 1989; 24:593-598. (Pubitemid 19170955)
44. Jackson SJ, Leahy FE, McGowan AA, et al. Delayed gastric emptying in the obese: an assessment using the noninvasive (13)C-octanoic acid breath test. Diab Obes Metab 2004; 6:264-270. (Pubitemid 38807800)
45. Medico CJ, Walsh P. Pharmacotherapy in the critically ill obese patient. Crit Care Clin 2010; 26:679-688.
46. Wojcicki J, Jaroszynska M, Drozdzik M, et al. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects. Biopharm Drug Dispos 2003; 24:211-218. (Pubitemid 36939693)
47. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999; 37:8-19. (Pubitemid 29043392)
48. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
49. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470. (Pubitemid 29135798)
50. Cirillo M, Anastasio P, De Santo NG. Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant 2005; 20:1791-1798. (Pubitemid 41222590)
51. Verhave JC, Fesler P, Ribstein J, et al. Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis 2005; 46:233-241. (Pubitemid 41040351)
52. Aggarwal N, Porter AC, Tang IY, et al. Creatinine-based estimations of kidney function are unreliable in obese kidney donors. J Transplant 2012; 2012:872894.
53. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612.
54. Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009; 66:642-648.
55. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 1988; 84:1053-1060.
56. Nankivell BJ. Creatinine clearance and the assessment of renal function. Aust Prescriber 2001; 24:15-17. (Pubitemid 32144588)
57. Mouton JW, Ambrose PG, Canton R, et al. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 2011; 14:107-117. Up-to-date discussion of PK-PD relationships and other dosing considerations.
58. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37:840-851.
59. Barger A, Fuhst C, Wiedemann B. Pharmacological indices in antibiotic therapy. J Antimicrob Chemother 2003; 52:893-898. (Pubitemid 38008406)
60. Theuretzbacher U. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. Clin Infect Dis 2012; 54:1785-1792.
61. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39:605-609.
62. Schwartz SN, Pazin GJ, Lyon JA, et al. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis 1978; 138:499-505. (Pubitemid 9032744)
63. Korsager S. Administration of gentamicin to obese patients. Int J Clin Pharmacol Ther Toxicol 1980; 18:549-553. (Pubitemid 11247535)
64. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998; 54:621-625. (Pubitemid 28531423)
65. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994; 16:513-518. (Pubitemid 24296745)
66. Vance-Bryan K, Guay DR, Gilliland SS, et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993; 37:436-440. (Pubitemid 23072585)
67. Leong JV, Boro MS, Winter M. Determining vancomycin clearance in an overweight and obese population. Am J Health Syst Pharm 2011; 68:599-603.
68. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325-327.
69. Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507-514.
70. Lodise TP, Lomaestro B, Graves J, DrusanoGL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52:1330-1336. (Pubitemid 351521995)
71. Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother 2012; 67:1305-1310. Summary of vancomycin dosing in obese patients.
72. Brink AJ, Richards GA, Cummins RR, Lambson J. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Int J Antimicrob Agents 2008; 32:455-458.
73. Wilson AP, Gruneberg RN, Neu H. Dosage recommendations for teicoplanin. J Antimicrob Chemother 1993; 32:792-796.
74. Wilson AP, Gruneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994; 4 (SUPPL. 1): 1-30.
75. Deman HVJ, Willems L, Spriet I. Dosing of piperacillin/tazobactam in a morbidly obese patient. J Antimicrob Chemother 2012; 2012:782-783.
76. Newman D, Scheetz MH, Adeyemi OA, et al. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother 2007; 41:1734-1739. (Pubitemid 47479805)
77. Zakrison TL, Hille DA, Namias N. Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam. Surg Infect (Larchmt) 2012; 13:38-42.
78. Wyeth Pharmaceuticals Inc. (March 2007) PipracilTM US Product Information, Philadelphia, PA. [Accessed on 9 July 2012]
79. Wyeth Pharmaceuticals Inc. (May 2012) ZosynTM US Product Information, Philadelphia, PA. [Accessed on 9 July 2012].
80. Edmiston CE, Krepel C, Kelly H, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? Surgery 2004; 136:738-747. (Pubitemid 39311298)
81. Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 1989; 106:750-756.
82. Ho VP, Nicolau DP, Dakin GF, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect 2012; 13:33-37. Describes dosing and expected duration of efficacy of perioperative cephazolin dosing.
83. Cefazolin for Injection US Product Information, Sagent Pharmaceuticals. http://www.sagentpharma.com/Products/Cefazolin/Catalog/Cefazolin-PI1. pdf. [Accessed on 9 July 2012]
84. Rich BS, Keel R, Ho VP, et al. Cefepime dosing in the morbidly obese patient population. Obes Surg 2012; 22:465-471. Describes a recommended regimen to achieve T>MIC 60%.
85. Chen M, Nafziger AN, Drusano GL, et al. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 2006; 50:1222-1227.
86. Itani KM, Jensen EH, Finn TS, et al. Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery. Surg Infect 2008; 9:131-137. (Pubitemid 351563820)
87. Merck and Co Inc (Feb 2012) InvanzTM US Product Information. http://www.merck.com/product/usa/pi-circulars/i/invanz/invanz-pi.pdf. [Accessed on 1 September 2012]
88. Pea F, Cojutti P, Sbrojavacca R, et al. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother 2011; 45:e37.
89. AstraZeneca Pharmaceuticals (December 2010) MerremTM US Product Information, Wilmington, DE. http://www1.astrazeneca-us.com/pi/merremiv. pdf. [Accessed 10 July 2012]
90. Taccone FS, Cotton F, Roisin S, et al. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012; 56:2129-2131.
91. Bristol-Myers Squibb Pharmaceuticals (July 2008) AzactamTM Australian Approved Product Information Noble Park, Victoria, Australia. http://www.pbs.gov.au/meds/pi/bqpazact10709.pdf [Accessed 6 July 2012]
92. Boccazzi A, Langer M, Mandelli M, et al. The pharmacokinetics of aztreonam and penetration into the bronchial secretions of critically ill patients. J Antimicrob Chemother 1989; 23:401-407. (Pubitemid 19097947)
93. Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005; 45:48-56.
94. Rayner CR, Forrest A, Meagher AK, et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42:1411-1423. (Pubitemid 38054365)
95. Caldwell JB, Nilsen AK. Intravenous ciprofloxacin dosing in a morbidly obese patient. Ann Pharmacother 1994; 28:806. (Pubitemid 24200943)
96. Allard S, Kinzig M, Boivin G, et al. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Therapeut 1993; 54:368-373. (Pubitemid 23316172)
97. Luque S, Grau S, Valle M, et al. Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient. J Antimicrob Chemother 2011; 66:1653-1654.
98. Kees MG, Weber S, Kees F, Horbach T. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother 2011; 66:2330-2335.
99. Bayer Australia Ltd (October 2011) Avelox1Australian Product Information, Pymble, NSW, Australia. http://www.bayerresources.com.au/resources/uploads/PI/ file9312.pdf. [Accessed on 11 July 2012]
100. Mayne Pharma International (December 2008) Eryc1 Australian Product Information, Salisbury South, SA, Australia. https://www.ebs.tga.gov.au/ebs/ picmi/picmirepository.nsf/pdf?OpenAgent&idCP-2010-PI-02149-3. [Accessed on 10 July 2012]
101. Van Bambeke F. 'Erythromycin' in Grayson ML, Crowe S, McCarthy J et al. Kucers' The use of antibiotics: A clinical review of antibacterial, antifungal and antiviral drugs. 6th ed. Hodder Arnold, London; 2010. pp. 751-769.
102. Abbott Laboratories (July 2012) BiaxinTM US Product Information, North Chicago, IL. http://www.rxabbott.com/pdf/biapi.pdf. [Accessed on 10 July 2012]
103. Abbott Australasia http://www.aspenpharma.com.au/product-info/pi/PI- Klacid.pdf. (April 2011) KlacidTM Australian Product Information, Botany NSW. [Accessed on 10 July 2012]
104. Bedford Laboratories Inc. (September 2004) Doxycycline 100mg Injection, US Product Information, Bedford OH. http://bidocs.boehringer-ingelheim. com/BIWebAccess/ViewServlet.ser?docBaserenetnt&folderPath/Pres cribingInformation/PIs/BenVenue-BedfordLabs/55390-110-10DCY100MG/5539011010. [Accessed on 10 July 2012]
105. Mayne Pharma International (January 2009) DoryxTM Australia Product Information, Salisbury South SA, Australia. https://www.ebs.tga.gov.au/ebs/ picmi/picmirepository.nsf/pdf?OpenAgent&idCP-2010-PI-02155-3. [Accessed on 10 July 2012]
106. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49:220-229. (Pubitemid 40065796)
107. Rubinstein E, Vaughan D. Tigecycline: a novel glycylcycline. Drugs 2005; 65:1317-1336. (Pubitemid 41043889)
108. Van Wart SA, Owen JS, Ludwig EA, et al. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob Agents Chemother 2006; 50:3701-3707. (Pubitemid 44684884)
109. G.D. Searle LLC (Division of Pfizer) (April 2010) FlagylTM US Product Information, New York, NY. [Accessed on 9 July 2012]
110. Mastrobattista JM, Klebanoff MA, Carey JC, et al. The effect of body mass index on therapeutic response to bacterial vaginosis in pregnancy. Am J Perinatol 2008; 25:233-237.
111. Halilovic J, Heintz BH, Brown J. Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect 2012; 65:128-134. Investigates a number of antibiotics where inadequate dosing was achieved, with particular attention to cotrimoxazole and clindamycin (first data on both of these antibiotics).
112. Teva Pharmaceuticals USA (October 2006) Sulphamethoxazole and Trimethoprim Injection USP, US Product Information. Sellersville, PA http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setidb89b5502-ce87-45a6-a43c- 9891da3cfca4. [Accessed on 10 July 2012]
113. Roche Products Pty Ltd (2011). Bactrim Australian Product Information. Dee Why NSW. http://www.roche-australia.com/fmfiles/re7229005/downloads/ antibiotics/bactrim-pi.pdf. [Accessed on 11 September 2012]
114. Pfizer Australia (May 2009) Dalacin CTM Phosphate Injection, Australian Product Information West Ryde NSW. http://pfizer.com.au/sites/au/Pro ducts/Leaflets/PI-DalacinCPhosphateInjectio-271.pdf. [Accessed on 10 July 2012]
115. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother 1999; 43:623-629. (Pubitemid 29109529)
116. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99. (Pubitemid 17225088)
117. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925-942. (Pubitemid 39447034)
118. Patel N, Pai MP, Rodvold KA, et al. Vancomycin: we can't get there from here. Clin Infect Dis 2011; 52:969-974.
119. Kanazawa N, Matsumoto K, Ikawa K, et al. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication. J Infect Chemother 2011; 17:297-300.
120. Anaya DA, Dellinger EP. The obese surgical patient: a susceptible host for infection. Surg Infect 2006; 7:473-480. (Pubitemid 44857100)
121. Toma O, Suntrup P, Stefanescu A, et al. Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection. Anesth Analg 2011; 113:730-737.
122. Gendall KA, Raniga S, Kennedy R, Frizelle FA. The impact of obesity on outcome aftermajor colorectal surgery. Dis ColonRectum2007;50:2223-2237. (Pubitemid 350284550)
123. Merkow RP, Bilimoria KY, McCarter MD, Bentrem DJ. Effect of body mass index on short-term outcomes after colectomy for cancer. J Am Coll Surg 2009; 208:53-61.
124. Leader WG, Tsubaki T, Chandler MH. Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients. Am J Hosp Pharm 1994; 51:2125-2130. (Pubitemid 24279980)
125. Bauer LA, Blouin RA, Griffen WO Jr., et al. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm 1980; 37:519-522. (Pubitemid 10070697)
126. Blouin RA, Mann HJ, S., et al. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 1979; 26:508-512. (Pubitemid 10214576)
127. Ortega A, Aldaz A, Giraldez J, Brugarolas A. Relationship between pharmacokinetic parameters of gentamicin and patient characteristics and/or clinical data in patients with solid organ tumours. Pharm World Sci 1999; 21:227-232. (Pubitemid 29485015)
128. Blouin RA, Brouwer KL, Record KE, et al. Amikacin pharmacokinetics in morbidly obese patients undergoing gastric-bypass surgery. Clin Pharm 1985; 4:70-72. (Pubitemid 15167279)
129. Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21:575-580. (Pubitemid 12070524)
130. Penzak SR, Gubbins PO, Rodvold KA, Hickerson SL. Therapeutic drug monitoring of vancomycin in a morbidly obese patient. Ther Drug Monit 1998; 20:261-265. (Pubitemid 28248845)
131. Hall RG 2nd, Payne KD, Bain AM, et al. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med 2008; 121:515-518. (Pubitemid 351695516)
132. Leonard AE, Boro MS. Vancomycin pharmacokinetics in middle-aged and elderly men. Am J Hosp Pharm 1994; 51:798-800. (Pubitemid 24096236)
133. Rushing TA, Ambrose PJ. Clinical application and evaluation of vancomycin dosing in adults. J Pharm Technol 2001; 17:33-38. (Pubitemid 32298248)
134. Reynolds DC, Waite LH, Alexander DP, Deryke CA. Performance of a vancomycin dosage regimen developed for obese patients. Am J Health Syst Pharm 2012; 69:944-950.
135. Truong J, Levkovich BJ, Padiglione AA. Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Intern Med J 2012; 42:23-29.
136. Barbour A, Schmidt S, Rout WR, et al. Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents 2009; 34:231-235.
137. Yost RL, Derendorf H. Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit 1986; 8:189-194. (Pubitemid 16084176)
138. Mann HJ, Buchwald H. Cefamandole distribution in serum, adipose tissue, and wound drainage in morbidly obese patients. Drug Intell Clin Pharm 1986; 20:869-873. (Pubitemid 16010361)
139. Pevzner L, Swank M, Krepel C, et al. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol 2011; 117:877-882.
140. Vance-Bryan K, Larson TA, Rotschafer JC, Toscano JP. Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1992; 36:2334-2337.
141. Bubalo JS, Munar MY, Cherala G, et al. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother 2009; 53:428-434.
142. Pai MP, Mercier RC, Allen SE. Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency. Ann Pharmacother 2006; 40:553-558.
143. Stein GE, Schooley SL, Peloquin CA, et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005; 39:427-432. (Pubitemid 40270909)
144. Mersfelder TL, Smith CL. Linezolid pharmacokinetics in an obese patient. Am J Health System Pharm 2005; 62:464.
145. Tsuji Y, Hiraki Y, Matsumoto K, et al. Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient. Scand J Infect Dis 2012; 44:626-629.
146. Utrup TR, Mueller EW, Healy DP, et al. High-dose ciprofloxacin for serious Gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. Ann Pharmacother 2010; 44:1660-1664.
147. Hollenstein UM, Brunner M, Schmid R, Muller M. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int J Obes Relat Metab Disord 2001; 25:354-358. (Pubitemid 32209810)
148. Seeger JD, West WA, Fife D, et al. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Safety 2006; 15:784-792. (Pubitemid 44762709)
149. Abdullahi M, Annibale B, Capoccia D, et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg 2008; 18:1450-1454.
150. Cerqueira RM, Manso MC, Correia MR, et al. Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery: fourteen days superior to seven days? Obes Surg 2011; 21:1377-1381.
151. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006; 58:256-265. (Pubitemid 44294934)
152. Bulik CC, Wiskirchen DE, Shepard A, et al. Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother 2010; 54:5209-5213.
153. ClinicalTrials.gov. Pharmacokinetics of tigecycline in morbidly obese subjects http://clinicaltrials.gov/ct2/show/NCT01560143. [Accessed 1 September 2012]
154. Langebrake C, Bernhardt F, Baehr M, et al. Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation. Int J Clin Pharm 2011; 33:918-924.
155. Yew WW, Leung CC. Update in tuberculosis 2007. Am J Respir Crit Care Med 2008; 177:479-485.
156. Leung CC, Lam TH, Chan WM, et al. Lower risk of tuberculosis in obesity. Arch Intern Med 2007; 167:1297-1304. (Pubitemid 46998502)
157. Geiseler PJ, Manis RD Jr., Maddux MS. Dosage of antituberculous drugs in obese patients. Am Rev Respir Dis 1985; 131:944-946. (Pubitemid 15065931)
158. Viriyayudhakorn S, Thitiarchakul S, Nachaisit S, et al. Pharmacokinetics of quinine in obesity. Trans Royal Soc Trop Med Hyg 2000; 94:425-428. (Pubitemid 30662354)
159. Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, et al. Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru. PloS One 2011; 6:e27610. [Epub 2011 Nov 16]
160. Hasenbosch RE, Alffenaar JW, Koopmans SA, et al. Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects. Int J Tuberc Lung Dis 2008; 12:967-971.
161. Roberts JA, Kruger P, Paterson DL, Lipman J. Antibiotic resistance: what's dosing got to do with it? Crit Care Med 2008; 36:2433-2440.